Clinical trial

Icotinib for Completed Resected IB NSCLC With EGFR Mutation

NCT02264210

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2015-01-01

PhasePHASE2

Study timeline

Study start (actual)2015-01-01Date precision: month

Registry last updated2024-09-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lung Neoplasmsunresolved

Squamous Cell Lung Cancerunresolved

Adenocarcinoma of the Lungunresolved

Adenosquamous Cell Lung Cancerunresolved

Large Cell Lung Cancerunresolved

Bronchial Neoplasmsunresolved

Stage IB Non-small Cell Lung Cancerunresolved

Interventions

Sponsors & collaborators

Sun Yat-sen Universitylead sponsor

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02264210 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.